View abstract. Yamaori S, Maeda C, Yamamoto I, Watanabe K. Differential inhibition of human cytochrome P450 2A6 and 2B6 by significant phytocannabinoids. Forensic Toxicol 2011; 29:117 -24. Yamaori S, Okamoto Y, Yamamoto I, Watanabe K. Cannabidiol, a significant phytocannabinoid, as a powerful atypical inhibitor for CYP2D6. Drug Metab Dispos 2011; 39( 11 ):2049 -56. View abstract.
Cannabidiol was inefficient for manic episode of bipolar affective disorder. J Psychopharmacol 2010; 24( 1 ):135 -7. View abstract. Zuardi AW, Cosme RA, Graeff FG, Guimaraes FS. Results of ipsapirone and cannabidiol on human speculative anxiety. J Psychopharmacol 1993; 7(1 Suppl):82 -8. View abstract. Zuardi AW, Crippa JA, Hallak JE, et al. Cannabidiol for the treatment of psychosis in Parkinson's disease.
View abstract. Zuardi AW, Crippa JA, Hallak JE, et al. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res 2006; 39( 4 ):421 -9. View abstract. Zuardi AW, Morais SL, Guimaraes FS, Mechoulam R. Antipsychotic impact of cannabidiol. J Clin Psychiatry 1995; 56( 10 ):485 -6. View abstract. Zuardi AW. Cannabidiol: from an inactive cannabinoid to a drug with large spectrum of action.
View abstract. Ames, F. R. and Cridland, S. Anticonvulsant impact of cannabidiol. S.Afr. Medication. J. 1-4-1986; 69( 1 ):14. View abstract. Barnes, M. P. Sativex: scientific effectiveness and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain. Professional. Opin. Pharmacother. 2006; 7( 5 ):607 -615. Need More Info? . Collin, C., Davies, P., Mutiboko, I. K., and Ratcliffe, S.
Eur. J.Neurol. 2007; 14( 3 ):290 -296. View abstract. Collin, C., Ehler, E., Waberzinek, G., Alsindi, Z., Davies, P., Powell, K., Notcutt, W., O'Leary, C., Ratcliffe, S., Novakova, I., Zapletalova, O., Pikova, J., and Ambler, Z. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in topics with signs of spasticity due to numerous sclerosis.
Res. 2010; 32( 5 ):451 -459. View abstract. Consroe, P., Kennedy, K., and Schram, K. Assay of plasma cannabidiol by capillary gas chromatography/ion trap mass spectroscopy following high-dose repeated daily oral administration in humans. Pharmacol Biochem. Behav. 1991; 40( 3 ):517 -522. View abstract. Consroe, P., Laguna, J., Allender, J., Snider, S., Stern, L., Sandyk, R., Kennedy, K., and Schram, K.
Pharmacol Biochem. Behav. 1991; 40( 3 ):701 -708. View abstract. Crippa, J. A., Zuardi, A. W., Garrido, G. E., Wichert-Ana, L., Guarnieri, R., Ferrari, L., Azevedo-Marques, P. M., Hallak, J. E., Mc, Guire, P. K., and Filho, Busatto G. Impacts of cannabidiol (CBD) on regional cerebral blood circulation. Neuropsychopharmacology 2004; 29( 2 ):417 -426. View abstract. Crippa, J.